Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-12 10:44 am Purchase |
2025-03-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Wellington Management Group LLP | 5,996,873 9.200% |
689,547 (+12.99%) |
Filing History |
| 2025-05-12 10:36 am Sale |
2025-03-31 | 13G | Kymera Therapeutics, Inc. KYMR |
FMR LLC | 4,409,234 6.800% |
-699,907 (-13.70%) |
Filing History |
| 2025-04-30 11:12 am Purchase |
2025-03-31 | 13G | Kymera Therapeutics, Inc. KYMR |
The Vanguard Group | 5,231,392 8.050% |
1,233,828 (+30.86%) |
Filing History |
| 2025-02-10 10:25 am Purchase |
2024-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Wellington Management Group LLP | 5,307,326 8.200% |
688,967 (+14.92%) |
Filing History |
| 2024-11-14 4:31 pm Sale |
2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 4,173,216 6.400% |
-794,898 (-16.00%) |
Filing History |
| 2024-11-14 1:22 pm Purchase |
2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR |
T. Rowe Price Associates, Inc. | 6,645,474 10.300% |
646,218 (+10.77%) |
Filing History |
| 2024-11-14 09:30 am Purchase |
2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR |
Avoro Capital Advisors LLC | 7,750,000 9.990% |
3,975,000 (+105.30%) |
Filing History |
| 2024-11-12 10:32 am Purchase |
2024-11-08 | 13G | Kymera Therapeutics, Inc. KYMR |
FMR LLC | 5,109,141 7.933% |
2,761,614 (+117.64%) |
Filing History |
| 2024-11-08 10:52 am Sale |
2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR |
Wellington Management Group LLP | 4,618,359 7.170% |
-197,199 (-4.10%) |
Filing History |
| 2024-08-22 4:15 pm Purchase |
2024-08-21 | 13D | Kymera Therapeutics, Inc. KYMR |
Baker Bros. Advisors LP | 6,001,262 9.300% |
3,556 (+0.06%) |
Filing History |
| 2024-04-01 08:57 am Purchase |
2024-03-28 | 13D | Kymera Therapeutics, Inc. KYMR |
Baker Bros. Advisors LP | 5,997,706 9.800% |
1,778 (+0.03%) |
Filing History |
| 2024-02-14 09:15 am Sale |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Avoro Capital Advisors LLC | 3,775,000 6.800% |
-75,000 (-1.95%) |
Filing History |
| 2024-02-13 5:08 pm Purchase |
2023-12-29 | 13G | Kymera Therapeutics, Inc. KYMR |
The Vanguard Group | 3,997,564 6.730% |
337,257 (+9.21%) |
Filing History |
| 2024-02-12 10:07 am Purchase |
2024-01-31 | 13G | Kymera Therapeutics, Inc. KYMR |
T. Rowe Price Associates, Inc. | 5,999,256 10.100% |
658,842 (+12.34%) |
Filing History |
| 2024-02-12 10:03 am Purchase |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
T. Rowe Price Associates, Inc. | 5,340,414 9.600% |
961,255 (+21.95%) |
Filing History |
| 2024-02-09 4:03 pm Sale |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 4,968,114 8.400% |
-98,811 (-1.95%) |
Filing History |
| 2024-02-08 10:21 am Purchase |
2023-12-29 | 13G | Kymera Therapeutics, Inc. KYMR |
Wellington Management Group LLP | 4,815,558 8.680% |
224,469 (+4.89%) |
Filing History |
| 2024-01-29 3:26 pm Purchase |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
BlackRock Inc. BLK |
3,566,611 6.400% |
231,710 (+6.95%) |
Filing History |
| 2024-01-23 10:31 am Sale |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
STATE STREET CORP STT |
1,894,279 3.410% |
-951,942 (-33.45%) |
Filing History |
| 2024-01-10 4:52 pm Purchase |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Baker Bros. Advisors LP | 5,995,928 10.800% |
3,116,103 (+108.20%) |
Filing History |